WO2022090807A3 - Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same - Google Patents

Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same Download PDF

Info

Publication number
WO2022090807A3
WO2022090807A3 PCT/IB2021/000776 IB2021000776W WO2022090807A3 WO 2022090807 A3 WO2022090807 A3 WO 2022090807A3 IB 2021000776 W IB2021000776 W IB 2021000776W WO 2022090807 A3 WO2022090807 A3 WO 2022090807A3
Authority
WO
WIPO (PCT)
Prior art keywords
tetrahydrocannabivarin
cannabigerol
methods
same
antidote
Prior art date
Application number
PCT/IB2021/000776
Other languages
French (fr)
Other versions
WO2022090807A2 (en
Inventor
Mark Scott
David WEINKAUF
Original Assignee
Next Level Health Sciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Next Level Health Sciences Inc. filed Critical Next Level Health Sciences Inc.
Publication of WO2022090807A2 publication Critical patent/WO2022090807A2/en
Publication of WO2022090807A3 publication Critical patent/WO2022090807A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Antidote compositions are disclosed that contain cannabigerol (CBG) and/or tetrahydrocannabivarin (THCV) that can be used to offset THC-induced biological effects, particularly for THC-containing edibles.
PCT/IB2021/000776 2020-10-30 2021-11-01 Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same WO2022090807A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063108008P 2020-10-30 2020-10-30
US63/108,008 2020-10-30

Publications (2)

Publication Number Publication Date
WO2022090807A2 WO2022090807A2 (en) 2022-05-05
WO2022090807A3 true WO2022090807A3 (en) 2022-06-16

Family

ID=81384473

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2021/000776 WO2022090807A2 (en) 2020-10-30 2021-11-01 Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same

Country Status (1)

Country Link
WO (1) WO2022090807A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015915A2 (en) * 2022-07-14 2024-01-18 Taac Naturals Enterprises, Llc Cannabinoid formulations

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRIPPA J ET AL.: "Pharmacological interventions in the treatment of the acute effects of cannabis: a systemic review of literature", HARM REDUCTION JOURNA L, vol. 9, no. 7, 25 January 2012 (2012-01-25), XP021118638, ISSN: 1477- 7517, [retrieved on 20220413], DOI: 10.1186/1477-7517-9-7 *
SKOLNICK PHIL; CRYSTAL ROGER: "Cannabinoid(CB-1) receptor antagonists: a molecular approach to treating acute cannabinoid overdose", JOURNAL OF NEURAL TRANSMISSION, SPRINGER VIENNA, VIENNA, vol. 127, no. 2, 31 December 2019 (2019-12-31), Vienna, pages 279 - 286, XP037029319, ISSN: 0300-9564, DOI: 10.1007/s00702-019-02132-7 *
VEMURI KIRAN, RAGHAV JIMIT, MAKRIYANNIS ALEXANDROS: "Antidotes for Acute Cannabinoid Intoxication", THE FASEB JOURNAL, vol. 33, no. S1, 1 April 2019 (2019-04-01), US, pages 804.2 - 804.2, XP009537367, ISSN: 0892-6638, DOI: 10.1096/fasebj.2019.33.1_supplement.804.2 *

Also Published As

Publication number Publication date
WO2022090807A2 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2022015272A (en) Inhibitors of kras g12c protein and uses thereof.
BRPI0507593A (en) cis-isomers-containing compositions of a carotenoid compound and process
Shi et al. α-Lipoic acid protects against the cytotoxicity and oxidative stress induced by cadmium in HepG2 cells through regeneration of glutathione by glutathione reductase via Nrf2/ARE signaling pathway
WO2019133770A3 (en) Glycolate oxidase inhibitors for the treatment of disease
NO20060977L (en) Mitokinone derivatives used as mitochondrial mole-seeking antioxidants
BRPI0717458A8 (en) ORAL AND/OR PARENTERAL COSMETIC USE OF GLUCOSAMINE AND THE ASSOCIATION OF GLUCOSAMINE AND AT LEAST ONE POLYPHENOL COMPOUND, COSMETIC PROCESS, COMPOSITION FOR ORAL ADMINISTRATION, AND, FOOD SUPPLEMENT OR FUNCTIONAL FOOD
WO2020086747A3 (en) Ssao inhibitors and uses thereof
MX2022014007A (en) Compounds as bcl-2 inhibitors.
MX2023002233A (en) Phospholipid compounds and uses thereof.
ECSP22083174A (en) MULTI-SPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
DOP2022000229A (en) MULTI-SPECIFIC HEAVY CHAIN ANTIBODIES WITH MODIFIED HEAVY CHAIN CONSTANT REGIONS
WO2022090807A3 (en) Cannabigerol and tetrahydrocannabivarin antidote formulations and methods of using the same
ZA202202376B (en) Difluorohaloallylamine sulfone derivative inhibitors of lysyl oxidases, methods of preparation, and uses thereof
Young et al. C-phycocyanin alleviates osteoarthritic injury in chondrocytes stimulated with H2O2 and compressive stress
MX2022015601A (en) Compound for the treatment of coronaviral infections.
WO2021158635A8 (en) Anti-viral compositions and methods of use
BR112021023927A2 (en) Compound and pharmaceutical composition
BR112013019394A2 (en) use of an agent
Sarriá et al. Nitroderivatives of olive oil phenols protect HepG2 cells against oxidative stress
NO20092763L (en) Isosorbide mononitrate derivatives for the treatment of intestinal disorders
BR112018072298A2 (en) treatment of Zika virus infections using alpha-glucosidase inhibitors
MX2021013656A (en) Antibiotic cannabinoid-terpene formulations.
MX2022011576A (en) Nlrp3 modulators.
BR112022023318A2 (en) MAXI-K POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF FRAGILE X-ASSOCIATED DISORDERS
BR112022026670A2 (en) VISCOSITY LOWERING EXCIPIENTS AND COMBINATIONS THEREOF FOR HIGHLY CONCENTRATED PROTEIN FORMULATIONS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21885439

Country of ref document: EP

Kind code of ref document: A2